Connect with us

Stocks

3 Short Squeeze Penny Stocks To Buy For Under $5 Right Now

Do these penny stocks have short squeeze potential?
The post 3 Short Squeeze Penny Stocks To Buy For Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Published

on

Penny stocks are highly speculative, high-risk, and have the potential to produce big windfalls if you know some basics. The last two years have been a rollercoaster ride in the stock market. Today is no different, and CPI data is an early catalyst, with Consumer Prices leaping 7% for the year through December.

The last time this figure was at these levels was 1982. But since this figure wasn’t “as bad” as some expected, broader markets pushed higher during premarket trading on Wednesday. This has sparked some interest in potential short-squeeze plays as bullish traders look to play against bearish bets that stocks would fall after CPI figures were revealed. Today we take a closer look at a few penny stocks with high short interest.


Penny Stocks TL;DR 30-Second Summary

  • Penny stocks are well-known for their higher risk profiles and potential for above average returns
  • Today retail traders may be looking at potential short squeeze penny stocks following the release of CPI data
  • Consumer Prices rose 7% for the year in December, the highest since 1982
  • Since the figure wasn’t outside of Wall Street expectations, traders seemed to take that as a bullish indication leading to a rise in broad sector ETFs
  • Since there were bearish bets ahead of today’s CPI data, some traders are taking this as a high-sign to play the “short squeeze” opportunities that may be present
  • Today we look at a few penny stocks with higher short interest

The critical thing to remember is that not all penny stocks with higher short interest end up “squeezing.” However, if you’re looking for short squeeze stocks, the first step is finding the correct data. Today we’ll look at a few that can be bought for less than $5 and higher short float percentages right now. Will there be a squeeze as the market turns bullish following new CPI data?

Short Squeeze Penny Stocks To Buy For Under $5

  1. Stran & Company (NASDAQ: STRN)
  2. Senseonics Holdings (NYSE: SENS)
  3. Vinco Ventures Inc. (NASDAQ: BBIG)

1. Stran & Company (NASDAQ: STRN)

Like some of the others on this list of penny stocks, Stran & Co has come under pressure recently. But new developments have come to light that may have helped bring more momentum back to the market. In this case, Strand & Company is a marketing solutions provider that dropped heavily earlier in the year. But a new contract could have built back some of the bullish sentiment that was lost.

Read: Check These 3 Penny Stocks Out For Your Morning Watchlist

In particular, the company announced a multi-year contract with “a large nationally recognized healthcare company.” Stran plans on providing incentive products and literature for driving consumer health behaviors. In response, Andy Shape, President and CEO of Stran, commented, “We believe the healthcare market represents a significant, yet largely untapped, opportunity to utilize promotional products to help drive positive and healthy consumer behaviors.”

Is STRN A Short Squeeze Stock?

In looking at short float data from Fintel.IO, the short float percentage on STRN stock sits around 10.8% right now. While this may be on the lower end of the spectrum, it seems to be something that at least a few retail traders are making a note of in the stock market today.

2. Senseonics Holdings (NYSE: SENS)

The last month has seen Senseonics shares trading in a relatively consistent range between $2.60 and $3 as the market continues digesting the latest string of headlines. The company reported mixed earnings in November, which sent the stock tumbling. However, this week Senseonics reiterated its 2021 guidance and said that it expects fiscal ’21 global net revenue to be in the middle of that guidance range of $12 million to $15 million. In addition, the market has perked up this week as it awaits a potential approval from the FDA.

This relates to the company’s glucose monitor technology, Eversense. “We understand that the FDA is at full capacity managing the backlog of COVID-19 related filings creating longer than expected review timelines. We are confident a decision regarding approval of the 180-day system will be made in the coming weeks as the FDA continues to clear out the backlog,” said Tim Goodnow, Ph.D., President and Chief Executive Officer of Senseonics.

Senseonics’ Eversense and Eversense XL have tiny sensors inserted completely under patients’ skin. The sensors communicate with a smart transmitter worn over the sensor. Then, every 5 minutes, data is sent to a mobile app for a patient to record. As the market awaits the FDA’s decision, speculation has played a role, and SENS stock has responded in kind.

Is SENS a Short Squeeze Stock?

According to Fintel’s data, the current percentage sits around 23.6% right now. Thanks to pending FDA decisions, SENS stock could be one to watch in January based on this recent speculative bet. But remember that nothing is confirmed, so if the FDA decision isn’t in favor of the company, things could be much different in the market.

short squeeze penny stocks to buy under 5 Senseonics SENS stock chat

3. Vinco Ventures Inc. (NASDAQ: BBIG)

Another one of the penny stocks that’s gotten beaten up a bit recently is Vinco Ventures. Thanks to several significant catalysts, it was a big win earlier this year. These included a TikTok app competitor app (Lomotif), a cryptocurrency spin-off, bitcoin mining equipment, and other operating segments, including entertainment production, via the TV series, Preach & feature film, Camp Hideout. These developments culminated in the market via a move from under $2 to over $12.

At the same time, much of this progress was overshadowed by a big earnings miss late last year. For instance, EPS for Q3 came in at a loss of $7.59, which was down from a loss of $0.30 the previous year. Sales also declined, year-over-year. But with plenty of irons on the fire and specific initiatives (like the entertainment production) to come to fruition in the first half of the year, BBIG stock remains on watch for some traders.

Is BBIG A Short Squeeze Stock?

Should you watch BBIG stock for a short squeeze? Like most things, it all depends. But as a starting point, Fintel shows a short float percentage of roughly 22.5% right now.

short squeeze penny stocks to buy under 5 Vinco Ventures BBIG stock chat

Are Penny Stocks Worth The Risk?

If you’re looking for penny stocks to buy, risk comes with the territory. The way you handle the risk sets profitable traders apart from the rest. When it comes to a short squeeze, things can move quickly. So quickly that if you aren’t ready to act quickly, you could miss opportunities on both the buy and sell side of the trade. If you’re new to penny stocks, take a look at some of these articles to get your trader education up to speed:


If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!


The post 3 Short Squeeze Penny Stocks To Buy For Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Government

Pfizer Inc (NYSE: PFE) To Acquire Global Blood Therapeutics For $5 Billion

According to sources familiar with the matter, the Wall Street Journal reported that Pfizer Inc (NYSE: PFE) was in advanced discussions to acquire pharmaceutical…

Published

on

According to sources familiar with the matter, the Wall Street Journal reported that Pfizer Inc (NYSE: PFE) was in advanced discussions to acquire pharmaceutical company Global Blood Therapeutics (NASDAQ: GBT) for $5 billion.

Pfizer, too, acquired Global Blood Therapeutics 

Pfizer wants to close a deal soon, but there are still other interested parties, according to the article.

Global Blood Therapeutics, which manufactures Oxbryta, the blood disorder medication, saw its shares jump 44%  on Friday afternoon to a two-year high. As of Thursday’s closing, the company’s market cap was $3.12 billion.

A spokesman for Global Blood stated the company does not “comment on market rumors or speculation,” while Pfizer declined to respond on the matter.

With plenty of cash left over after selling its COVID-19 vaccine, New York-based Pfizer is searching for deals that may generate billions of dollars annual sales by 2030.

Its $11.6 billion acquisition of migraine medication manufacturer Biohaven Pharmaceutical Holding (NASDAQ: BHVN) in May was the most recent in a series of purchases that also included Trillium Therapeutics and Arena Pharmaceuticals in recent years.

Oxbryta received approval last year for sickle cell disease management 

In 2019, the US government approved Global Blood’s Oxbryta to manage sickle cell disease in individuals aged 12 and over. The oral medication was approved in December 2021 to treat the illness in younger children. The drug’s sales increased by almost 50% to $194.7 million in 2021.

After a gloomy start to the calendar year, when a lack of significant purchases and clinical-stage treatment failures lowered investor morale and restricted funding, the biotech dealmaking pace has recently picked up again.

Also, Amgen Inc (NASDAQ: AMGN) also decided to purchase ChemoCentryx Inc on Thursday for $3.7 billion to obtain access to a possible breakthrough medication for inflammatory illnesses. AstraZeneca’s $39 billion acquisition of Alexion Pharmaceuticals in 2020 has put the realm of immune diseases in the limelight. The deal, which was announced before trading opened, will also give the corporation control of at least two investigational immune disorders medicines.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

The post Pfizer Inc (NYSE: PFE) To Acquire Global Blood Therapeutics For $5 Billion appeared first on Wall Street PR.

Read More

Continue Reading

Science

AEMD: Positive Results in a Range of Conditions, Including COVID-19 & Monkey Pox

By M. Marin
NASDAQ:AEMD
READ THE FULL AEMD RESEARCH REPORT
Expanding the Potential Indications for Hemopurifier Treatment
Aethlon Medical’s (NASDAQ: AEMD)…

Published

on

By M. Marin

NASDAQ:AEMD

READ THE FULL AEMD RESEARCH REPORT

Expanding the Potential Indications for Hemopurifier Treatment

Aethlon Medical's (NASDAQ: AEMD) clinical trials are moving forward and expanding, as AEMD continues to demonstrate the effectiveness of its lead product, the Aethlon Hemopurifier®, in a broad range of viruses and conditions in single patient emergency use cases and in in vitro analysis, including COVID-19 and various variants and Monkey Pox, among others. The Aethlon Hemopurifier® is being studied in a severe COVID-19 clinical trial under the company's open IDE (Investigational Device Exemption) for life-threatening viral infections.

The safety and feasibility of the Hemopurifier is being evaluated in an Early Feasibility Study (EFS) that will enroll up to 40 COVID-19 ICU patients. The first patient was enrolled in this study in June 2022 and has completed the Hemopurifier treatment. AEMD has nine fully activated hospitals that are actively screening patients for the trial.

In addition to this study, the Hemopurifier has demonstrated positive results in two severely ill patients under individual emergency use and in in vitro analysis. The Hemopurifier has produced positive results in binding seven variants of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) virus in vitro, as discussed in an article1  that AEMD's CEO Dr. Charles J. Fisher Jr. and the company's Chief Medical Officer Dr. Steven LaRosa contributed to.

The company is also conducting a study of the impact of the ...

Full story available on Benzinga.com

Read More

Continue Reading

Economics

Where Are Interest Rates Headed? Is The Fed Correct Or The Eurodollar Curve?

Where Are Interest Rates Headed? Is The Fed Correct Or The Eurodollar Curve?

Authored by Mike Shedlock via MishTalk.com,

The Eurodollar curve…

Published

on

Where Are Interest Rates Headed? Is The Fed Correct Or The Eurodollar Curve?

Authored by Mike Shedlock via MishTalk.com,

The Eurodollar curve implies four quarter-point cuts are on the way starting in 2023. The Fed believes otherwise. Let's discuss stock market implications.

Data from CME and Fed via Wall Street Journal.

Eurodollar Curve

The eurodollar curve has nothing to do with euros or dollars. Rather it is an interest rate curve and one of the world's most widely traded futures.

After peaking at about 3.9% this year, eurodollar betters believe the Fed will then cut rates all the way down to 2.8%. 

Five Not-Quite-Impossible Things the Market Believes

Wall Street Journal Contributor James Macintosh discussed the above chart in Five Not-Quite-Impossible Things the Market Believes

  1. Inflation is transitory. 

  2. The Fed realizes this in time.

  3. The jobs market cools enough to slow wage rises. 

  4. But not so much it means falling household spending.

  5. So consumer spending rises in real terms. 

In reference to the led chart, Macintosh says "The first assumption is the hardest to believe."

I disagree. The hardest thing to believe is the overall goldilocks scenario and that the current rally makes any sense at all. 

Inflation may easily come down if the Fed tightens too much too fast causing a severe recession. What would that do to corporate profits? 

But assume otherwise, that inflation does not come down more. What would that do to corporate profits? 

While any of the first three points may easily be correct, the combination of all five being correct and that stocks will rise in a goldilocks scenario is what I find hard to believe.

Is the Market Forward Looking?

Goldilocks proponents will tell you that the market is forward looking. 

The market isn't forward looking and never was. It is a coincident indicator of current sentiment, wildly wrong at major turns.

If the market was forward looking, what precisely was it looking forward to at the November 2007 peak with recession starting the next month? 

What was it looking forward to at the 1929 peak, the 1933 bottom, the 2009 bottom or any other top or bottom?

The Fed Will Hike Until It Breaks Something

I believe the eurodollar curve is more likely to be correct than the Fed. When has the Fed gotten much of anything correct?

The eurodollar view has two ways to win. The first is the Fed actually does tame inflation to the degree that it wants.

That's possible in a severe enough recession. And the global picture is easily weak enough for that to happen.

The second way the eurodollar curve might be correct is if the Fed breaks the credit market. 

The Fed would immediately reverse course, regardless of inflation, should that happen. 

Neither a credit event nor strong recession would be good for the stock market.

The least likely thing is that the Fed achieves a goldilocks soft landing. Yet, assume that happens. 

Macintosh says, and I agree, "The bull case that stocks and corporate bonds are pricing requires the combination of low joblessness and wage rises to allow spending to rise faster than inflation even after pandemic savings run out. But not so much faster that it hits capacity constraints and accelerates inflation."

The problem with goldilocks is stocks are priced so much beyond perfection that they may decline anyway. 

Globally Speaking 

  1. China Does Surprise Rate Cut to Help Its Economy, But It Won't Work

  2. German Costs to Ship by Barge are up Twenty Times and May Soon Be Impossible

  3. UK Average Electricity Cost Will Soar to $5,370 Per Year By 2023

  4. US Industries Are Buckling Under Pressure of Surging Electricity Costs

Good luck with goldilocks, especially with the Fed still hiking. 

*  *  *

Please Subscribe to MishTalk Email Alerts.

Tyler Durden Wed, 08/17/2022 - 09:45

Read More

Continue Reading

Trending